On August 31, 2022, Gambacorti-Passerini, Carlo; Nicolini, Franck Emmanuel; Larson, Richard A.; Aroldi, Andrea; Fontana, Diletta; Piazza, Rocco; le Coutre, Philipp; Antolini, Laura; Assouline, Sarit published an article.Computed Properties of 380843-75-4 The title of the article was Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. And the article contained the following:
Rates of 142 nominal disease categories were significantly increased in CML patients vs. the general population, even after excluding the initial 6 mo of treatment, when factors associated with the presence of uncontrolled leukemia could be involved in generating the reported abnormalities. Based on these data our general policy for CML patients is to actively look for early diagnosis of second cancers. Whether this result derives from increased susceptibility, increased monitoring of patients or both,it remains to be established. This could be linked to the preferential inhibition of PDGFR over ABL1 operated by imatinib. A second important aspect of this paper relates to the use of second generation TKI (2GEN). This was particularly evident for nilotinib and dasatinib, for which sufficient data were available, while insufficient data were present regarding the use of bosutinib and ponatinib. Not surprisingly, Nilotinib resulted in an increased risk of cardiovascular events and diabetes development, while dasatinib use showed increased risks of pleural effusions and infections. Since CML patients may be taking these TKIs for many years, it is in cumbent on physicians to manage and minimize treatment-related risks and co-morbid conditions. In conclusion,the report is important issue in the management of CML: when a normal life expectancy is the goal of the therapy, the safety of the choosen TKI becomes of paramount importance, especially for first line therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4
The Article related to human chronic myeloid leukemia cardiovascular disease tki dasatinib safety, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics